BidaskClub downgraded shares of Aratana Therapeutics (NASDAQ:PETX) from a strong-buy rating to a buy rating in a report released on Friday.
PETX has been the topic of several other reports. Zacks Investment Research raised shares of Aratana Therapeutics from a hold rating to a buy rating and set a $6.50 price objective on the stock in a research note on Wednesday, January 2nd. ValuEngine raised shares of Aratana Therapeutics from a sell rating to a hold rating in a research note on Monday, October 22nd. HC Wainwright set a $10.00 price objective on shares of Aratana Therapeutics and gave the company a buy rating in a research note on Monday, November 5th. Finally, TheStreet raised shares of Aratana Therapeutics from a d rating to a c- rating in a research note on Wednesday, November 21st. Two investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. The company has a consensus rating of Buy and an average price target of $7.50.
Shares of PETX opened at $4.37 on Friday. The company has a debt-to-equity ratio of 0.02, a quick ratio of 2.70 and a current ratio of 3.17. The firm has a market capitalization of $296.12 million, a price-to-earnings ratio of -4.51 and a beta of 1.78. Aratana Therapeutics has a 1 year low of $3.67 and a 1 year high of $7.16.
Aratana Therapeutics (NASDAQ:PETX) last announced its quarterly earnings data on Thursday, November 1st. The biopharmaceutical company reported ($0.13) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.16) by $0.03. The company had revenue of $21.56 million for the quarter, compared to analysts’ expectations of $5.70 million. Aratana Therapeutics had a negative net margin of 52.94% and a negative return on equity of 15.08%. As a group, equities research analysts expect that Aratana Therapeutics will post -0.25 EPS for the current year.
In other Aratana Therapeutics news, insider Ernst Heinen sold 19,308 shares of the business’s stock in a transaction on Wednesday, November 7th. The shares were sold at an average price of $6.95, for a total transaction of $134,190.60. Following the sale, the insider now directly owns 135,694 shares in the company, valued at approximately $943,073.30. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Peter Steven St sold 11,513 shares of the business’s stock in a transaction on Tuesday, October 30th. The stock was sold at an average price of $5.86, for a total transaction of $67,466.18. Following the sale, the insider now owns 562,720 shares in the company, valued at $3,297,539.20. The disclosure for this sale can be found here. Insiders sold a total of 77,607 shares of company stock worth $476,116 over the last three months. 5.30% of the stock is currently owned by corporate insiders.
Hedge funds and other institutional investors have recently modified their holdings of the business. Hollencrest Capital Management purchased a new stake in shares of Aratana Therapeutics during the 4th quarter worth $153,000. MetLife Investment Advisors LLC purchased a new stake in shares of Aratana Therapeutics during the 3rd quarter worth $215,000. American Century Companies Inc. purchased a new stake in shares of Aratana Therapeutics during the 2nd quarter worth $195,000. Bank of Montreal Can boosted its position in shares of Aratana Therapeutics by 152.9% during the 3rd quarter. Bank of Montreal Can now owns 51,360 shares of the biopharmaceutical company’s stock worth $301,000 after purchasing an additional 31,053 shares in the last quarter. Finally, Acadian Asset Management LLC boosted its position in shares of Aratana Therapeutics by 69.8% during the 3rd quarter. Acadian Asset Management LLC now owns 194,746 shares of the biopharmaceutical company’s stock worth $1,137,000 after purchasing an additional 80,064 shares in the last quarter. Institutional investors own 67.92% of the company’s stock.
About Aratana Therapeutics
Aratana Therapeutics, Inc, a pet therapeutics company, focuses on the licensing, development, and commercialization of therapeutics for dogs and cats in the United States and Belgium. Its product portfolio includes multiple therapeutics and therapeutic candidates in development consisting of small molecule pharmaceuticals and biologics.
Featured Article: What are the economic characteristics of a bear market?
Receive News & Ratings for Aratana Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aratana Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.